Ir para o conteúdo principal

United StatesÚltimas notícias

Grafa
Health

Alvotech nears regulatory filing as Entyvio biosimilar meets study goals

Alvotech (NASDAQ:ALVO) announced positive top-line results from a pivotal clinical study for its biosimilar candidate to Entyvio, positioning the Icelandic biotech to challenge one of the top-selling gastrointestinal treatments in a $6.4 billion market.

Leia mais: Alvotech nears regulatory filing as Entyvio biosimilar meets study goals